The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells

The non-canonical Wnt signalling receptor ROR1 is aberrantly expressed in numerous cancers, including ovarian and endometrial cancer. We previously reported that silencing ROR1 could inhibit the proliferation and metastatic potential of ovarian and endometrial cancer cells in vitro. Zilovertamab is...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Dongli, Kaufmann, Gunnar F., Breitmeyer, James B., Dickson, Kristie-Ann, Marsh, Deborah J., Ford, Caroline E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033071/
https://www.ncbi.nlm.nih.gov/pubmed/35456672
http://dx.doi.org/10.3390/pharmaceutics14040837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033071/
https://www.ncbi.nlm.nih.gov/pubmed/35456672
http://dx.doi.org/10.3390/pharmaceutics14040837

Ejemplares similares